A 59-year-old man with BMI 31 kg/m² and T2D on metformin asks whether SGLT2 inhibitors benefit kidneys and heart. Which is true?...

Question

A 59-year-old man with BMI 31 kg/m² and T2D on metformin asks whether SGLT2 inhibitors benefit kidneys and heart. Which is true?

Accepted Answer

SGLT2 inhibitors reduce risk of CKD progression and HF events independent of baseline A1c

Answer

They are only glucose-lowering and have no renal benefit

Answer

They are contraindicated if eGFR >60

Answer

They increase stroke risk and should be avoided

Answer

They replace the need for ACE inhibitors

us-abfm MCQ (SBA): Diabetes & CKD/HF Risk